Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT.

Cardiac uptake of 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) is frequently observed on FDG positron-emission tomography combined with computed tomography (PET-CT) performed for diagnosis, staging, and assessment of therapeutic response of lymphoma and solid cancers, despite careful patient preparation to limit myocardial glucose substrate utilisation. We illustrate the varied physiological patterns of cardiac FDG uptake, and show a spectrum of pathological conditions causing FDG uptake within myocardial and pericardial structures, due to clinically important benign and malignant diseases. Recognition and awareness of these various causes of FDG uptake in the heart, along with the appropriate use of correlative contrast-enhanced CT and magnetic resonance imaging (MRI) will facilitate correct interpretation.

Molecular imaging in the management of thyroid cancer.

Thyroid cancer is the most common endocrine malignancy in adults. The disease is classified into papillary, follicular, medullary and anaplastic types, each with characteristic histology and patterns of biological behavior. Diagnosis of thyroid cancer is usually made by needle aspiration of suspicious thyroid nodules. Disease management of well-differentiated thyroid cancer relies upon characteristic accumulation of radioisotopes of iodine that continues to play a central role in detection and treatment of disease. Recombinant human thyrotropin (rhTSH) is used as an alternative to thyroid hormone withdrawal to provide TSH stimulation necessary for diagnostic radioiodine scintigraphy and preparation for thyroid remnant ablation and cancer therapy. Hybrid SPECT/CT cameras combining functional scintigraphic information with CT anatomy are replacing stand-alone gamma cameras and these devices have been shown to outperform traditional planar and SPECT imaging techniques. Similarly, clinical application of novel radioisotopes like [124I]iodine with PET/CT for thyroid cancer imaging provides improved lesion resolution and direct tumor dosimetry. Alternative tracers such as [18F]fluorodeoxyglucose (FDG) can be used to evaluate well-differentiated thyroid cancers that no longer express the Na+/I- symporter, with a role in staging Hürthle cell, poorly differentiated, and anaplastic thyroid cancers. Medullary thyroid cancer recurrences are often difficult to detect using conventional imaging and traditional radionuclide studies, whereas [18F]FDG and [18F]fluorodihydroxyphenylalanine (DOPA) PET and PET/CT show promise for localizing the often elusive source (s) of elevated calcitonin in these patients.

Effect of phosphorylated mannans and pharmacological additions of zinc oxide on growth and immunocompetence of weanling pigs.

Three experiments were conducted to evaluate the efficacy of phosphorylated mannans (MAN) and pharmacological levels of ZnO on performance and immunity when added to nursery pig diets. Pigs (216 in each experiment), averaging 19 d of age and 6.2, 4.6, and 5.6 kg of BW in Exp. 1, 2, and 3, respectively, were blocked by BW in each experiment, and penned in groups of six. A lymphocyte blastogenesis assay was performed in each experiment to measure in vitro lymphocyte proliferation response. In Exp. 1, diets were arranged as a 2 x 2 factorial with two levels of Zn (200 and 2,500 ppm) and two levels of MAN (0 and 0.3% from d 0 to 10, and 0 and 0.2% from d 10 to 38). Zinc oxide increased (P < 0.05) ADG, ADFI, and G:F from d 0 to 10, and ADG and ADFI from d 10 to 24. In Exp. 2, diets were arranged as a 2 x 3 factorial with two levels of Zn (200 and 2,500 ppm) and three levels of MAN (0, 0.2, and 0.3%). Pigs fed 2,500 ppm Zn from d 0 to 10 had greater (P < 0.05) ADG, ADFI, and G:F than pigs fed 200 ppm Zn. From d 10 to 24, ADG was similar when pigs were fed 200 ppm Zn, regardless of MAN supplementation; however, ADG increased (P < 0.05) when 0.2% MAN was added to dietscontaining 2,500 ppm Zn (MAN x Zn interaction, P < 0.05). In Exp. 3, diets were arranged as a 2 x 3 factorial with two levels of MAN (0 and 0.3%) and three levels of Zn (200, 500, and 2,500 ppm). Zinc was maintained at 200 ppm from d 21 to 35, so only two dietary treatments (0 and 0.3% MAN) were fed during this period. Average daily gain was greater (P < 0.05) from d 7 to 21 when pigs were fed 2,500 ppm Zn compared with pigs fed 200 or 500 ppm Zn. The addition of MAN improved (P < 0.05) G:F from d 7 to 21 and d 0 to 35. Lymphocyte proliferation of unstimulated cells and phytohemagglutinin-stimulated cells was decreased (P < 0.05) in cells isolated from pigs fed MAN compared with cells isolated from pigs fed diets without MAN. Lymphocyte proliferation of pokeweed mitogen-stimulated cells isolated from pigs fed MAN was less (P < 0.05) than for pigs fed diets devoid of MAN when diets contained 200 ppm Zn; however, MAN had no effect on lymphocyte proliferation when the diet contained 500 or 2,500 ppm Zn (MAN x Zn interaction, P < 0.05). Although the magnitude of response to MAN was not equivalent to that of pharmacological concentrations of Zn, MAN mayimprove growth response when pharmacological Zn levels are restricted.

Effect of dietary mannan oligosaccharides and(or) pharmacological additions of copper sulfate on growth performance and immunocompetence of weanling and growing/finishing pigs.

Two experiments were conducted to determine the efficacy of mannan oligosaccharides (MOS) fed at two levels of Cu on growth and feed efficiency of weanling and growing-finishing pigs, as well as the effect on the immunocompetence of weanling pigs. In Exp. 1, 216 barrows (6 kg of BW and 18 d of age) were penned in groups of six (9 pens/treatment). Dietary treatments were arranged as a 2 x 2 factorial consisting of two levels of Cu (basal level or 175 ppm supplemental Cu) with and without MOS (0.2%). Diets were fed from d 0 to 38 after weaning. Blood samples were obtained to determine lymphocyte proliferation in vitro. From d 0 to 10, ADG, ADFI, and gain:feed (G:F) increased when MOS was added to diets containing the basal level of Cu, but decreased when MOS was added to diets containing 175 ppm supplemental Cu (interaction, P < 0.01, P < 0.10, and P < 0.05, respectively). Pigs fed diets containing 175 ppm Cu from d 10 to 24 and d 24 to 38 had greater (P < 0.05) ADG and ADFI than those fed the basal level of Cu regardless of MOS addition. Pigs fed diets containing MOS from d 24 to 38 had greater ADG (P < 0.05) and G:F (P < 0.10) than those fed diets devoid of MOS. Lymphocyte proliferation was not altered by dietary treatment. In Exp. 2, 144 pigs were divided into six pigs/pen (six pens/treatment). Dietary treatments were fed throughout the starter (20 to 32 kg BW), grower (32 to 68 kg BW), and finisher (68 to 106 kg BW) phases. Diets consisted of two levels of Cu (basal level or basal diet + 175 ppm in starter and grower diets and 125 ppm in finisher diets) with and without MOS (0.2% in starter, 0.1% in grower, and 0.05% in finisher). Pigs fed supplemental Cu had greater (P < 0.05) ADG and G:F during the starter and grower phases compared to pigs fed the basal level of Cu. During the finisher phase, ADG increased when pigs were fed MOS in diets containing the basal level of Cu, but decreased when MOS was added to diets supplemented with 125 ppm Cu (interaction, P < 0.05). Results from this study indicate the response of weanling pigs fed MOS in phase 1 varied with level of dietary Cu. However, in phase 2 and phase 3, diets containing either MOS or 175 ppm Cu resulted in improved performance. Pharmacological Cu addition improved gain and efficiency during the starter and grower phases in growing-finishing pigs, while ADG response to the addition of MOS during the finisher phase seems to be dependent upon the level of Cu supplementation.